Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.57 |
| ▸ | HTR2C | P28335 | 11/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.57 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6587822 | 0.89 | HTR2A (0.73) | HTR2AHTR2CKCNH2DRD2CA12 | |
| SCHEMBL7024062 | 0.88 | HTR2A (0.70) | HTR2AHTR2CKCNH2DRD2HTR7 | |
| SCHEMBL6586480 | 0.85 | HTR2A (0.78) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL7022479 | 0.82 | HTR2A (0.63) | HTR2AHTR2CKCNH2DRD2HTR7 | |
| SCHEMBL7027981 | 0.82 | HTR2A (0.71) | HTR2AHTR2CKCNH2DRD2HTR7 | |
| SCHEMBL7035227 | 0.82 | HTR2A (0.63) | HTR2AHTR2CKCNH2DRD2HTR7 | |
| SCHEMBL7029502 | 0.82 | HTR2A (0.82) | HTR2AHTR2CKCNH2DRD2HTR7 | |
| SCHEMBL7030971 | 0.82 | HTR2A (0.73) | HTR2AHTR2CKCNH2DRD2HTR7 | |
| SCHEMBL7025260 | 0.81 | HTR2A (0.61) | HTR2AHTR2CKCNH2DRD2HTR7 | |
| SCHEMBL7034106 | 0.80 | HTR2A (0.62) | HTR2AHTR2CKCNH2DRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147084-B1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME (GB) | 2004-05-19 | — | — | EP | claimed |
| US-20030203889-A1 | Phenylsulphonyl derivatives as 5-HT receptor ligands | MERCK & CO., INC. | 2003-10-30 | — | — | US | claimed |
| US-6559166-B1 | A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore | MERCK SHARP & DOHME LTD. | 2003-05-06 | — | — | US | claimed |
| EP-1147084-A1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2001-10-24 | — | — | EP | claimed |
| WO-2000043362-A1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2000-07-27 | — | — | WO | claimed |
| US-6777430-B2 | A DERIVATIVES WITH ATTACHED TO AN N-ARYLALKYL-SUBSTITUTED AZETIDINE, PYRROLIDINE OR PIPERIDINE RING; A SERATONIN RECEPTOR ANTAGONISTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER SCHIZOPHRENIA, DEPRESSION | MERCK SHARP & DOHME LTD. | 2004-08-17 | — | — | US | disclosed |
| EP-1147084-B1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-20030203889-A1 | Phenylsulphonyl derivatives as 5-HT receptor ligands | MERCK & CO., INC. | 2003-10-30 | — | — | US | disclosed |
| US-6559166-B1 | A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore | MERCK SHARP & DOHME LTD. | 2003-05-06 | — | — | US | disclosed |
| EP-1147084-A1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043362-A1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203889-A1 | Phenylsulphonyl derivatives as 5-HT receptor ligands | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.